novo 60 days, page-5

Luk,
Your $1 figure is way below figures from reputable analysts from 12 months ago. The trial results are very positive despite the appaling announcements. The analyses aluded to above relate to only one condidtion (we have at least four indications) and also assume a maximum of 5% of total market. A drug without side effects will sweep the market. You do the numbers. Whatever your answer, $1 or $2 is way too low. I don't try to predict the market, I just do a fumdamental analysis and eventually the market will catch up. All this company needs is some decent honest management.